SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Capricor Therapeutics, Inc. is a clinical-stage biotechnology company, which focuses on the development of transformative cell and exosome-based therapeutics for treating Duchenne muscular dystrophy (“DMD”), a rare form of muscular dystrophy which results in muscle degeneration and premature death, and other diseases with unmet medical needs. Its product candidate consists of CAP-1002, Engineered Exosomes, CAP-2003, and Exosome-Based Vaccine. The company was founded on June 17, 1996 and is headquartered in San Diego, CA.

Capricor Therapeutics Inc

Capricor Therapeutics is currently the focus of an FDA advisory committee meeting evaluating the efficacy of deramiocel for Duchenne muscular dystrophy, with the community closely tracking whether the committee will prioritize the totality of patient testimonials and peer-reviewed Lancet data over the FDA's statistical concerns. Investors are highly attentive to the potential for a regulatory outcome that could either validate the company's long-term clinical efforts or necessitate further trials.

SoFi Technologies, Inc. is a financial service platform, which engages in the provision of student loan refinancing options to the private student loan market. It operates through the following segments: Lending, Technology Platform, and Financial Services. The Lending segment offers personal loans, student loans, home loan products, and related servicing activities. The Technology Platform segment focuses on technology products and solutions revenue. The Financial Services segment includes the SoFi Money product, SoFi Invest product, SoFi Credit Card product, SoFi Relay personal finance management product, and other financial services. The company was founded in April 2011 and is headquartered in San Francisco, CA.

SoFi Technologies Inc

SoFi Technologies is trending due to a significant sell-off following a strong earnings report that featured a triple beat and raised guidance, leaving the community divided between long-term bulls accumulating the dip and frustrated investors questioning the stock's persistent negative price action. Discussions are heavily focused on the disconnect between the company's record growth and its market performance, with many participants debating the impact of management's guidance on interest rate hikes and broader macro-economic uncertainty.

Hims & Hers Health, Inc. operates a telehealth consultation platform. It connects consumers to healthcare professionals, enabling them to access medical care for mental health, sexual health, dermatology and primary care. The company was founded in 2017 and is headquartered in San Francisco, CA.

Hims & Hers Health Inc - Ordinary Shares - Class A

Hims & Hers Health Inc

Hims & Hers Health Inc. is experiencing significant volatility following a Federal Trade Commission lawsuit alleging deceptive privacy and billing practices, a development that has triggered intense debate within the community regarding regulatory risk versus long-term growth potential. While some investors remain optimistic about the company's expansion into the peptide market and upcoming earnings, others are wary of the mounting legal pressure and are actively discussing the stock's vulnerability to short-selling activity.

Nebius Group NV is a technology company that provides infrastructure and services to AI builders worldwide. It offers Nebius AI, an AI-centric cloud platform provides full-stack infrastructure, including large-scale GPU clusters, cloud services, and developer tools. The company also operates through specialized brands: Toloka AI, which partners in data for generative AI development; TripleTen, an edtech platform focused on re-skilling individuals for tech careers; and Avride, which develops autonomous driving technology. Nebius Group was founded by Elena Kolmanovskaya, Ilya Segalovich, Mikhail Fadeev, and Arkady Volozh in 1989 and is headquartered in Amsterdam, the Netherlands.

Nebius Group N.V. - Ordinary Shares - Class A

Nebius Group N.V. 

Nebius Group is facing intense volatility as the market debates AI infrastructure valuations and capital expenditure concerns ahead of upcoming earnings. While many retail investors are aggressively 'buying the dip' on the belief that a short squeeze is imminent, some traders remain cautious, pointing to ongoing institutional pressure and technical weakness in the broader AI sector.

Vertiv Holdings Co. engages in the design, manufacture, and service of critical digital infrastructure technology for data centers, communication networks, and commercial and industrial environments. The firm also offers power management products, switchgear and busbar products, thermal management products, integrated rack systems, modular solutions, and management systems for monitoring and controlling digital infrastructure. It operates through the following geographical segments: Americas, Asia Pacific, and Europe, Middle East, and Africa (EMEA). The Americas segment includes products and services sold for applications within the data center, communication networks and commercial and industrial markets in North America and Latin America. The Asia Pacific segment consists of products and services sold for applications within the data center, communication networks and commercial and industrial markets throughout Greater China, Asia, and India. The EMEA segment focuses on products and services sold for applications within the data center, communication networks, and commercial and industrial markets in Europe, Middle East, and Africa. The company was founded in 1946 and is headquartered in Westerville, OH.

Vertiv Holdings Co - Ordinary Shares - Class A

Vertiv Holdings Co

Vertiv Holdings is experiencing increased volatility as investors weigh the company's long-term leadership in AI data center cooling and power infrastructure against broader market rotation and high valuation concerns. The community remains focused on whether Vertiv's ongoing manufacturing expansions and strategic role in hyperscaler capex projects will justify its premium pricing and overcome recent short-term price pressure.

CoreWeave, Inc. engages in the powers of the creation and delivery of the intelligence that drives innovation. It offers a solution used by organizations of all sizes that require sophisticated AI computing, from the largest of enterprises to small, well-funded start-ups. The company was founded by Michael Intrator, Brian Venturo, Peter Salanki, and Brannin McBee on September 21, 2017 and is headquartered in Livingston, NJ.

CoreWeave Inc. - Ordinary Shares - Class A

CoreWeave Inc

CoreWeave is facing significant selling pressure as investors weigh concerns over high capital intensity and balance sheet leverage against the company's long-term potential as an AI infrastructure leader. While bulls argue that the stock is oversold and due for a rebound based on anticipated big tech capex spending, the community remains deeply divided, with many debating whether the current price action signals a bottoming process or further downside risk.

Seagate Technology Holdings Plc operates as holding company that is engaged in the development, production, and distribution of data storage products and electronic data storage solutions. Its products include hard disk drives, solid state hybrid drives, solid state drives, peripheral component interconnect express cards, serial advanced technology attachment controllers, storage subsystems and computing solutions. The firm offers its products under the Backup Plus and Expansion product lines, and Maxtor and LaCie brands. The company was founded in 1978 and is headquartered in Singapore.

Seagate Technology Holdings Plc

Seagate is trending as investors weigh strong quarterly results and bullish guidance against broader volatility in the memory and storage sector. While the community highlights concerns over cyclicality and semiconductor sell-offs, many remain focused on the company's long-term growth driven by AI-fueled demand for mass-capacity storage.

Invesco QQQ Trust Series 1 - Invesco QQQ Trust Series 1

QQQ is trending as market participants brace for a critical Fed interest rate decision, with the community actively debating whether a potential rate hike or dovish hold will trigger a massive rally or deeper selloff. Investors are closely monitoring high-volatility price action and negative gamma levels, while venting frustration over perceived institutional manipulation and the broader impact of AI spending on sector-wide stability.

Verra Mobility Corp. engages in the provision of smart mobility technology solutions. It operates through the following segments: Government Solutions, Commercial Services, and Parking Solutions. The Government Solutions segment offers automated safety solutions to state and local governments. The Commercial Services segment provides toll and violation management solutions by partnering with the fleet management and rental car companies. The Parking Solutions segment includes a suite of parking software and hardware solutions. The company was founded in 2004 and is headquartered in Mesa, AZ.

Verra Mobility Corp - Ordinary Shares - Class A

Verra Mobility is trending as investors capitalize on a significant price correction following the termination of a major client contract and a leadership transition, with many pointing to the company's profitability and low P/E ratio as key drivers for a potential rebound. Community discussions are heavily focused on the stock being drastically oversold, leading to active debates on whether the massive sell-off was a market overreaction that presents a long-term value opportunity.

Direxion Shares ETF Trust - Direxion Daily Semiconductor Bull 3X ETF

Direxion Daily Semiconductor Bull 3X Shares

SOXL is currently experiencing high volatility as investors weigh the impact of an intense semiconductor sell-off against hopes for a potential rebound fueled by earnings season and upcoming Federal Reserve policy decisions. The community is heavily divided, with many retail traders aggressively buying the dip on expectations of a historic bounce, while others argue that the sector's previous gains are unraveling due to excessive leverage and weakening macroeconomic sentiment.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Is SYRE Stock a Buy Now or a Wait-and-See Biotech Story Today

SYRE has surged on pipeline progress and a strong cash position, but with no product revenue and key trial data still ahead, is the risk already priced in?

SYRE and Spyre Ride New IBD Trends in Biotech Drug Design

SYRE is targeting major IBD drug trends with long-acting antibodies and combination therapies, but its future still hinges on clinical trial results.

Spyre Therapeutics Stock Outlook Hinges on 2026 Study Catalysts

The investment case for Spyre Therapeutics is built around a straightforward but high-risk question: can its broad IBD pipeline produce meaningful clinical proof-of-concept data? 

What's Going On With Spyre Therapeutics Stock On Wednesday?

Spyre Therapeutics falls 12% amid major insider stock sales. Explore the technical data and market sentiment for SYRE.read more...

Merck's Anti-TL1A Antibody Meets Goal in Ulcerative Colitis Study

MRK's tulisokibart meets goals in a late-stage ulcerative colitis study, strengthening a key pipeline asset as the company looks beyond Keytruda.

SYRE Completes Enrollment in SKYWAY Basket Study on SPY072, Stock Up

Spyre Therapeutics gains after completing enrollment in all SKYWAY phase II sub-studies evaluating SPY072 across three rheumatic diseases.

Upcoming Phase 2 Readouts Could Redefine These Biotech Stocks

Upcoming Phase 2 Readouts Could Redefine These Biotech Stocks $NTHI, $ORKA, $ABVX, $CGEM, $SYRE, $APGE

Spyre Therapeutics (NASDAQ:SYRE) Price Target Raised to $97.00 at Citigroup

Citigroup upped their target price on shares of Spyre Therapeutics from $64.00 to $97.00 and gave the company a "buy" rating in a research note on Wednesday...

Insider Selling: Spyre Therapeutics (NASDAQ:SYRE) CEO Sells 15,000 Shares of Stock

Spyre Therapeutics, Inc. (NASDAQ:SYRE - Get Free Report) CEO Cameron Turtle sold 15,000 shares of the company's stock in a transaction dated Friday, May 1st. The stock was sold at an average price of...

Spyre Therapeutics (NASDAQ:SYRE) Insider Sells $5,600,809.50 in Stock

Spyre Therapeutics, Inc. (NASDAQ:SYRE - Get Free Report) insider Sheldon Sloan sold 78,333 shares of Spyre Therapeutics stock in a transaction on Friday, May 1st. The shares were sold at an average...

Spyre Therapeutics, Inc. is a clinical-stage biotechnology company, which engages in the development of next-generation human enzyme therapeutics as disruptive solutions for rare and other high-burden diseases. Its product, Pegzilarginase, is in a Phase 3 pivotal trial for the treatment of Arginase 1 Deficiency. The company was founded by George Georgiou and David G. Lowe on December 16, 2013 and is headquartered in Waltham, MA.

Spyre Therapeutics Inc.

SYRE Stock Marks Best Session In About 3 Years — Here’s Why 

Equity

Bearish Sentiment

Hold rates steady

Cut 25 bps

Hike 25 bps

The Fed's July 28-29 meeting has markets debating a hold versus a hike, not a cut, with CME FedWatch pricing roughly a 65% chance of no change and rising odds of a September rate increase amid inflation running well above the 2% target. What do you expect the Fed to decide? Drop a comment with when you expect the first cut/hike to be.

What do you expect the Fed to decide at its FOMC meeting?  
 
Drop a comment with when you expect the first cut/hike to be.

Feed

News

Sentiment

Earnings

Fundamentals

Info

SYRESpyre Therapeutics Inc

Fundamentals

Latest SYRE News